BERLIN--(BUSINESS WIRE)-- Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III ...
Hosted on MSN
Bayer backs AskBio gene therapy push in Pompe disease: Early trial update and investor takeaways
Bayer AG (BAYRY) announced an update on their ongoing clinical study. Study Overview The PROGRESS-GT LOPD trial is an early-stage clinical study sponsored by AskBio, with Bayer as a collaborator, to ...
Genethon, a non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), began the new year with an R&D licensing deal for its gene therapy approach to ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accep ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
The rise of China, the buzz around AI, challenging global market dynamics, the recent surge in dealmaking and exciting new modalities were the talk of JPM this year.
First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...
Bayer AG’s BAYRY wholly owned, independently operated subsidiary BlueRock Therapeutics LP announced positive 36-month data from an early-stage study of bemdaneprocel, an investigational cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results